Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Chief Financial Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 931 |
Ending reported balance
After 2026-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-02 · Exercise / conversion · Acquired 374 · Balance 1,066 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Row 2 · 2026-01-02 · Sale · Disposed 135 · Balance 931 F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 726 |
Reported balance
After 2026-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-02 · Exercise / conversion · Disposed 374 · Balance 726 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
F-star Therapeutics, Inc.
Report date November 19, 2020 · Filed November 23, 2020
Section 16 reporting ended · disclosed 2020-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,867 |
Ending reported balance
After 2020-11-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-11-19 · Exercise / conversion · Acquired 3,750 · Balance 5,542 F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Row 2 · 2020-11-19 · Grant · Acquired 12,500 · Balance 18,042 F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Row 3 · 2020-11-20 · Sale · Disposed 175 · Balance 17,867 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-19 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F2: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis.
F2: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 374 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004565 · ownership.xml · derivative · entry 3 Firmani Lori · CIK 0001808248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726 Underlying: Common Stock · 374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 135 | $21.41 | $2,890.35 |
DisclosureSEC source: 0001193125-26-004565 · ownership.xml · nonDerivative · entry 2 Firmani Lori · CIK 0001808248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-004565 · ownership.xml · nonDerivative · entry 1 Firmani Lori · CIK 0001808248 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 374 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094572 · ownership.xml · derivative · entry 3 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 147 | $3.39 | $498.33 |
DisclosureSEC source: 0000950170-25-094572 · ownership.xml · nonDerivative · entry 2 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 692 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-094572 · ownership.xml · nonDerivative · entry 1 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000950170-25-002813 · ownership.xml · derivative · entry 4 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-03 F4 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on January 3, 2026 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 726 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002813 · ownership.xml · derivative · entry 3 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,474 Underlying: Common Stock · 726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 261 | $5.63 | $1,469.43 |
DisclosureSEC source: 0000950170-25-002813 · ownership.xml · nonDerivative · entry 2 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002813 · ownership.xml · nonDerivative · entry 1 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000950170-24-114385 · ownership.xml · derivative · entry 1 Firmani Lori · CIK 0001808248 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2034-10-09 F1 · derivative.exercise_date: The shares subject to such option vest in 48 equal monthly installments over four years from the Award Date, subject in each case to the grantee's continued service through the applicable vesting date. Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 16:12 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | SaleCommon Stock | 175 | $4.76 | $833.00 |
DisclosureSEC source: 0000905718-20-001130 · springbank_fm4nov192020.xml · nonDerivative · entry 3 Firmani Lori · CIK 0001808248 · VP of Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,867 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:12 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-20-001130 · springbank_fm4nov192020.xml · derivative · entry 4 Firmani Lori · CIK 0001808248 · VP of Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F2 · derivative.exercise_date: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. F2 · derivative.expiration_date: All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:12 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-20-001130 · springbank_fm4nov192020.xml · nonDerivative · entry 2 Firmani Lori · CIK 0001808248 · VP of Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,042 F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:12 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-20-001130 · springbank_fm4nov192020.xml · nonDerivative · entry 1 Firmani Lori · CIK 0001808248 · VP of Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.